S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
Renowned Economist issues startling prediction | America's Future   (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
3rd Massive Dollar Upheaval Has Started (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
Renowned Economist issues startling prediction | America's Future   (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
3rd Massive Dollar Upheaval Has Started (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
Renowned Economist issues startling prediction | America's Future   (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
3rd Massive Dollar Upheaval Has Started (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
Renowned Economist issues startling prediction | America's Future   (Ad)pixel
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
3rd Massive Dollar Upheaval Has Started (Ad)
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of  (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
LON:TRX

Tissue Regenix Group - TRX Share Forecast, Price & News

GBX 0.59
+0.01 (+1.72%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
0.58
0.60
50-Day Range
0.42
0.59
52-Week Range
0.33
0.74
Volume
72.28 million shs
Average Volume
23.19 million shs
Market Capitalization
£41.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TRX stock logo

About Tissue Regenix Group (LON:TRX) Stock

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Tissue Regenix Group Trading Up 2.6 %

Shares of TRX Stock opened at GBX 0.59 ($0.01) on Friday. Tissue Regenix Group has a 52-week low of GBX 0.33 ($0.00) and a 52-week high of GBX 0.74 ($0.01). The company has a debt-to-equity ratio of 23.80, a quick ratio of 2.59 and a current ratio of 5.06. The firm has a market capitalization of £41.58 million and a PE ratio of -5.86. The stock has a fifty day simple moving average of GBX 0.48 and a two-hundred day simple moving average of GBX 0.45.

Receive TRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter.

TRX Stock News Headlines

Tissue Regenix 'on a pathway to sustainability'
See More Headlines
Receive TRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter.

TRX Company Calendar

Last Earnings
9/02/2020
Today
8/19/2022
Next Earnings (Estimated)
9/07/2022

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
79
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£19.75 million
Cash Flow
GBX 0.10 per share
Book Value
GBX 0.50 per share

Miscellaneous

Outstanding Shares
7,035,795,000
Free Float
N/A
Market Cap
£41.51 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Daniel R. Lee
    CEO & Director
  • Mr. David Claiborne Cocke (Age 56)
    CFO & Exec. Director
    Comp: $330.15k
  • Ms. Christine Rowley
    Technical & Operations Director
  • Ms. Kirsten Lund
    Group Fin. Director & Company Sec.
  • Prof. Eileen Ingham
    Consultant













TRX Stock - Frequently Asked Questions

How have TRX shares performed in 2022?

Tissue Regenix Group's stock was trading at GBX 0.53 at the start of the year. Since then, TRX shares have increased by 10.6% and is now trading at GBX 0.59.
View the best growth stocks for 2022 here
.

When is Tissue Regenix Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 7th 2022.
View our TRX earnings forecast
.

How were Tissue Regenix Group's earnings last quarter?

Tissue Regenix Group plc (LON:TRX) posted its earnings results on Wednesday, September, 2nd. The company reported ($0.16) EPS for the quarter.

What other stocks do shareholders of Tissue Regenix Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tissue Regenix Group investors own include Argos Therapeutics (ARGSQ), TransEnterix (TRXC), Swedbank AB (publ) (SWDBY), Trevena (TRVN), Allied Minds (ALM), ArQule (ARQL), Boeing (BA), CIRCOR International (CIR), WisdomTree Middle East Dividend Fund (GULF) and W.W. Grainger (GWW).

What is Tissue Regenix Group's stock symbol?

Tissue Regenix Group trades on the London Stock Exchange (LON) under the ticker symbol "TRX."

How do I buy shares of Tissue Regenix Group?

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Tissue Regenix Group's stock price today?

One share of TRX stock can currently be purchased for approximately GBX 0.59.

How much money does Tissue Regenix Group make?

Tissue Regenix Group (LON:TRX) has a market capitalization of £41.51 million and generates £19.75 million in revenue each year.

How can I contact Tissue Regenix Group?

Tissue Regenix Group's mailing address is Innovation Way, YORK, YO10 5NY, United Kingdom. The official website for the company is www.tissueregenix.com. The company can be reached via phone at +44-1904-567609.

This page (LON:TRX) was last updated on 8/20/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.